| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
Form 4: Golestani Clark, Director
Bought 40,000 shares ($30K) · Received 25,000 shares as a grant or award |
| 09 Nov 2026 | 10-Q |
| 20 Oct 2026 |
8-K: Regulation FD Disclosure
New appointments of global quantum experts Shor, Paler, Devitt and Izmaylov further validate Zapata’s approach to quantum software |
| 13 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On October 9, 2026, Zapata Quantum, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). At the 2026 Annual Meeting, the Company’s stockholders voted (i) to elect three directors to hold office f... |
| 06 Oct 2026 |
8-K: Regulation FD Disclosure
Effort builds on prior collaboration to translate high-value use cases into practical applications running on IBM quantum computers |
| 23 Sep 2026 |
8-K: Regulation FD Disclosure
Drawing on Zapata’s pioneering quantum software expertise, the platform helps enterprises |
| 15 Sep 2026 |
8-K: Regulation FD Disclosure
Recognition reflects a successful ground-up restructuring that positions the |
| 14 Sep 2026 |
Proxy statement: annual meeting on October 9, 2026
say-on-pay vote |
| 04 Sep 2026 | PRELIMINARY PROXY STATEMENT |
| 14 Aug 2026 | FORM 424B3 |
| 14 Aug 2026 | FORM 10-Q FOR JUN 2026 |
| 12 Aug 2026 |
8-K: Regulation FD Disclosure
The partnership combines QuEra's fault-tolerant hardware roadmap with Zapata's application intelligence expertise to bridge the quantum applications gap |
| 11 Aug 2026 | FORM 424B3 |
| 10 Aug 2026 | EFFECT |
| 05 Aug 2026 |
8-K: Entry into a Material Definitive Agreement
On July 30, 2026, Zapata Quantum, Inc. (the “Company”) entered into an Exclusive Broker-Dealer and Leak-Out Management Agreement (the “B/D Agreement”) with Chardan Capital Markets LLC (the “B/D”), pursuant to which the B/D agreed to act ... |
| 09 Jul 2026 |
8-K: Regulation FD Disclosure
The Software Platform to Unlock Quantumʼs Potential July 2026 |
| 09 Jul 2026 | AMENDMENT NO 1 |
| 07 Jul 2026 |
8-K: Unregistered Sales of Equity Securities
CEO Sumit Kapur will discuss highlights including the Company's NVIDIA collaboration and quantum cancer research recognized as a Nature Biotechnology Top 10 |
| 05 Jun 2026 | FORM S-1 |
| 15 May 2026 | FORM 10-Q |
Loading...